Arcus Biosciences, Inc. has regained ownership of casdatifan, a potential treatment for clear cell renal cell carcinoma (ccRCC), after Gilead’s time-limited exclusive option rights to casdatifan expired. In addition, Arcus has announced the pricing of a $150 million common stock offering, which is subject to customary closing conditions and includes participation from new and existing institutional healthcare investors and Gilead. The financing is expected to fund Arcus through the anticipate...